<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101383</url>
  </required_header>
  <id_info>
    <org_study_id>GLARGIN-CL</org_study_id>
    <nct_id>NCT04101383</nct_id>
  </id_info>
  <brief_title>A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients</brief_title>
  <official_title>A Randomized Double Blinded Two-way Crossover Single-dose Pharmacokinetics and Pharmacodynamics Study of RinGlar® (LLC &quot;GEROPHARM&quot;, Russia) Versus Lantus® (Sanofi-Aventis) in Type 1 Diabetes Mellitus Patients Using the Euglycemic Clamp Technique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics and pharmacodynamics study of 2 formulation of insulin glargine (RinGlar®
      GEROPHARM vers. Lantus® Sanofi-Aventis)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized double blinded two-way crossover single-dose pharmacokinetics and
      pharmacodynamics study of RinGlar® (LLC &quot;GEROPHARM&quot;, Russia) versus Lantus® (Sanofi-Aventis)
      in Type 1 Diabetes Mellitus Patients using the euglycemic clamp technique
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Actual">February 16, 2018</completion_date>
  <primary_completion_date type="Actual">February 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>two-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This study was blinded for Sponsor, investigators and analytical laboratory</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>AUC GIR(0-t)</measure>
    <time_frame>0 hours (pre-dose), as well as at, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900, 960, 1020, 1080, 1140, 1200, 1260, 1320, 1380, 1440 minutes post-dose</time_frame>
    <description>Pharmacodynamic of insulin glargine by Assessment of GIR Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>-60, -30 and 0 hours (pre-dose), as well as at, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900, 960, 1020, 1080, 1140, 1200, 1260, 1320, 1380, 1440 minutes post-dose</time_frame>
    <description>Pharmacokinetics of insulin glargine by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Clamp Study</condition>
  <arm_group>
    <arm_group_label>RinGlar®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single subcutaneous administration of Lantus® in dose 0.6 Units/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RinGlar®</intervention_name>
    <description>Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg</description>
    <arm_group_label>RinGlar®</arm_group_label>
    <other_name>insulin glargine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lantus®</intervention_name>
    <description>Single subcutaneous administration of Lantus® in dose 0.6 Units/kg</description>
    <arm_group_label>Lantus®</arm_group_label>
    <other_name>insulin glargine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent.

          2. Caucasian males having confirmed diabetes mellitus type 1 (WHO criteria) for at least
             12 months prior to screening.

          3. Age of 18-65 (both incl.).

          4. HbA1С ≤ 8,0 %.

          5. Insulin therapy in stable doses at least 3 months. Total dose of insulin ≤ 1,2 IU/kg
             per day.

          6. At least 6 months of Lantus use.

          7. C-peptide ≤ 0,3 nM/L (or 0,5 ng/mL).

          8. Body mass index equal to 18.5-32.0 kg/m2.

          9. Subject must use, with their partner, methods of highly effective contraception
             throughout the study.

         10. Subject is able and willing to comply with the requirements of the study protocol.

        Exclusion Criteria:

          1. Acute inflammatory diseases within 3 weeks before the screening period.

          2. History or presence of uncontrolled diabetes mellitus for 6 months prior to screening.

          3. Clinically significant diabetes mellitus complications (proliferative retinopathy,
             severe diabetic neuropathy, diabetic nephropathy (CKD-EPI &lt; 60 mL/min/1,73 m2),
             diabetic foot).

          4. Clinically significant deviations in basic vital signs (blood pressure, heart rate,
             respiration rate, body temperature), ECG and lab tests.

          5. Deep vein thrombosis of lower extremities in a history of life or in a family history.

          6. Taking medications (excl. insulin and ACE-inhibitors), phytopreparations, biologically
             active supplements less than 14 days before screening.

          7. Donor blood donation or another blood loss, less than 3 months before the study.

          8. Recovery after surgery process.

          9. Mental, physical and other reasons that do not allow to adequately assess their
             behavior and properly fulfill the conditions of the research protocol, including
             psychiatric disorders.

         10. History of significant drugs abuse conditions for 3 years prior to screening.

         11. Positive testing for drugs.

         12. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5
             liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information
             about alcoholism.

         13. Positive testing for alcohol.

         14. Nicotine dependence (use of tobacco less than 6 months before the start of screening).

         15. Positive test results for hepatitis C or hepatitis B, HIV, syphilis.

         16. Presence of suspicions of an inflammatory disease of the urinary system as a result of
             urinalysis.

         17. Weighed allergic anamnesis.

         18. Presence of oncology disease in the anamnesis 5 years prior the start of screening.

         19. Organ transplantation in anamnesis (excl. cornea transplantation at least 3 month
             prior the IP administration).

         20. Participation in a clinical trial of any medications less than 3 months before the IP
             administration.

         21. Any other conditions that make it difficult, according to the informed opinion of the
             investigating physician, that volunteer participation in studies.

         22. History of hypersensitivity to insulin, heparin and excipients of the drugs using in
             study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Endocrinology Research Centre</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Insulin glargine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

